Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE)

M. Lia Palomba; Meletios A. Dimopoulos; Alessandra Tedeschi; Judith Trotman; Ramón García-Sanz; David MacDonald; Veronique Leblond; Beatrice Mahe; Charles Herbaux; Constantine Tam; Jeffrey V. Matous; Chaim Shustik; Efstathios Kastritis; Steven P. Treon; Jianling Li; Zeena Salman; Thorsten Graef; Christian Buske

doi:10.1016/J.CLML.2018.07.217

Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE)

M. Lia Palomba
, Meletios A. Dimopoulos
, Alessandra Tedeschi
, Judith Trotman
, Ramón García-Sanz
, David MacDonald
, Veronique Leblond
, Beatrice Mahe
, Charles Herbaux
, Constantine Tam
, Jeffrey V. Matous
, Chaim Shustik
, Efstathios Kastritis
, Steven P. Treon
, Jianling Li
, Zeena Salman
, Thorsten Graef
, Christian Buske

Memorial Sloan-Kettering Cancer Center
National and Kapodistrian University of Athens
ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
University of Sydney
Hospital Universitario de Salamanca, Salamanca, Spain
University of Ottawa
University of Paris
Centre Hospitalier Universitaire de Nantes, Nantes, France.
Centre Hospitalier Régional Universitaire de Lille, Institute of Hematolog-Tranfusion, Lille, France
Peter MacCallum Cancer Centre
Colorado Blood Cancer Institute, Denver, Colorado, United States
McGill University Health Centre
Harvard University
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California, United States
University of Ulm

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Lymphoma, Myeloma & Leukemia
Volume	18
DOIs	https://doi.org/10.1016/J.CLML.2018.07.217
State	Published - Sep 1 2018
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Hematology
Internal Medicine

Access to Document

10.1016/J.CLML.2018.07.217License: Unspecified

Cite this

Palomba, M. L., Dimopoulos, M. A., Tedeschi, A., Trotman, J., García-Sanz, R., MacDonald, D., Leblond, V., Mahe, B., Herbaux, C., Tam, C., Matous, J. V., Shustik, C., Kastritis, E., Treon, S. P., Li, J., Salman, Z., Graef, T., & Buske, C. (2018). Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE). Clinical Lymphoma, Myeloma & Leukemia, 18. https://doi.org/10.1016/J.CLML.2018.07.217

Palomba, ML, Dimopoulos, MA, Tedeschi, A, Trotman, J, García-Sanz, R, MacDonald, D, Leblond, V, Mahe, B, Herbaux, C, Tam, C, Matous, JV, Shustik, C, Kastritis, E, Treon, SP, Li, J, Salman, Z, Graef, T & Buske, C 2018, 'Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE)', Clinical Lymphoma, Myeloma & Leukemia, vol. 18. https://doi.org/10.1016/J.CLML.2018.07.217

@article{46685aa99a334d4aac2ad3cc1734308f,

title = "Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenstr{\"o}m{\textquoteright}s Macroglobulinemia (iNNOVATE)",

author = "Palomba, \{M. Lia\} and Dimopoulos, \{Meletios A.\} and Alessandra Tedeschi and Judith Trotman and Ram{\'o}n Garc{\'i}a-Sanz and David MacDonald and Veronique Leblond and Beatrice Mahe and Charles Herbaux and Constantine Tam and Matous, \{Jeffrey V.\} and Chaim Shustik and Efstathios Kastritis and Treon, \{Steven P.\} and Jianling Li and Zeena Salman and Thorsten Graef and Christian Buske",

note = "Ibrutinib, a once-daily inhibitor of Bruton's Tyrosine Kinase, is approved in the US and EU for the treatment of Waldenstr{\"o}m's macroglobulinemia (WM).",

year = "2018",

month = sep,

day = "1",

doi = "10.1016/J.CLML.2018.07.217",

language = "American English",

volume = "18",

journal = "Clinical Lymphoma, Myeloma \& Leukemia",

}

TY - JOUR

T1 - Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE)

AU - Palomba, M. Lia

AU - Dimopoulos, Meletios A.

AU - Tedeschi, Alessandra

AU - Trotman, Judith

AU - García-Sanz, Ramón

AU - MacDonald, David

AU - Leblond, Veronique

AU - Mahe, Beatrice

AU - Herbaux, Charles

AU - Tam, Constantine

AU - Matous, Jeffrey V.

AU - Shustik, Chaim

AU - Kastritis, Efstathios

AU - Treon, Steven P.

AU - Li, Jianling

AU - Salman, Zeena

AU - Graef, Thorsten

AU - Buske, Christian

N1 - Ibrutinib, a once-daily inhibitor of Bruton's Tyrosine Kinase, is approved in the US and EU for the treatment of Waldenström's macroglobulinemia (WM).

PY - 2018/9/1

Y1 - 2018/9/1

UR - https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(18)30966-2/fulltext

U2 - 10.1016/J.CLML.2018.07.217

DO - 10.1016/J.CLML.2018.07.217

M3 - Article

VL - 18

JO - Clinical Lymphoma, Myeloma & Leukemia

JF - Clinical Lymphoma, Myeloma & Leukemia

ER -

Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE)

Disciplines

Access to Document

Other files and links

Cite this